Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease

Gloria Biella, Massimo Franceschi, Francesca De Rino, Annalisa Davin, Giacomo Giacalone, Paola Brambilla, Panagiotis Bountris, Maria Haritou, Giuseppe Magnani, Filippo Martinelli Boneschi, Gianluigi Forloni, Diego Albani

Research output: Contribution to journalArticle

Abstract

One of the current challenge in Alzheimer's disease (AD) is the identification of reliable biomarkers that might improve diagnostic accuracy, possibly correlating with the disease progression and patient's response to therapy. As the clinically validated AD biomarkers evaluate cerebrospinal fluid (CSF) parameters, the need for less invasive diagnostic markers is well evident. To this respect, blood circulating cytokines or growth factors have provided some encouraging results, even though no clinically validated to date. In 2007 Ray et al suggested a panel of 18 circulating molecules that might increase AD diagnostic accuracy. In an attempt of replicating their data, we designed a multiplex fluorimetric assay comprising 16 independent analytes and covering 15 out of the 18 described proteins. We collected serum samples from three diagnostic groups: probable AD (n=33), matched healthy controls (CNT, n=23) and non AD demented (NAD, n=14). After correction for age, we found an increased level of EGF-1 in AD in comparison to CNT and NAD, while an increase of TRAIL-R4 was found in NAD. However, evaluation of specificity/ sensitivity by ROC curve analysis gave weak evidence of diagnostic accuracy (area under the curve = 0.63 and 0.66 for EGF and TRAIL-R4, respectively). Finally, we tried to find a diagnostic classifier by a multivariate algorithm. We found indication of diagnostic evidence for AD only, while NAD samples did not show a diagnostic pattern.

Original languageEnglish
Pages (from-to)40-45
Number of pages6
JournalAmerican Journal of Neurodegenerative Diseases
Volume2
Issue number1
Publication statusPublished - 2013

Fingerprint

Alzheimer Disease
Differential Diagnosis
NAD
Serum
Epidermal Growth Factor
ROC Curve
Biomarkers
Area Under Curve
Cerebrospinal Fluid
Disease Progression
Intercellular Signaling Peptides and Proteins
Cytokines
Sensitivity and Specificity
Proteins
Therapeutics

Keywords

  • Alzheimer's disease
  • Artificial neural networks
  • Diagnosis
  • EGF-1
  • Machine learning
  • Multiplex analysis
  • Multivariate classifier
  • Peripheral biomarkers

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease. / Biella, Gloria; Franceschi, Massimo; De Rino, Francesca; Davin, Annalisa; Giacalone, Giacomo; Brambilla, Paola; Bountris, Panagiotis; Haritou, Maria; Magnani, Giuseppe; Martinelli Boneschi, Filippo; Forloni, Gianluigi; Albani, Diego.

In: American Journal of Neurodegenerative Diseases, Vol. 2, No. 1, 2013, p. 40-45.

Research output: Contribution to journalArticle

Biella, G, Franceschi, M, De Rino, F, Davin, A, Giacalone, G, Brambilla, P, Bountris, P, Haritou, M, Magnani, G, Martinelli Boneschi, F, Forloni, G & Albani, D 2013, 'Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease', American Journal of Neurodegenerative Diseases, vol. 2, no. 1, pp. 40-45.
Biella, Gloria ; Franceschi, Massimo ; De Rino, Francesca ; Davin, Annalisa ; Giacalone, Giacomo ; Brambilla, Paola ; Bountris, Panagiotis ; Haritou, Maria ; Magnani, Giuseppe ; Martinelli Boneschi, Filippo ; Forloni, Gianluigi ; Albani, Diego. / Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease. In: American Journal of Neurodegenerative Diseases. 2013 ; Vol. 2, No. 1. pp. 40-45.
@article{d8f972740d2d4049b63b45f1862aa27b,
title = "Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease",
abstract = "One of the current challenge in Alzheimer's disease (AD) is the identification of reliable biomarkers that might improve diagnostic accuracy, possibly correlating with the disease progression and patient's response to therapy. As the clinically validated AD biomarkers evaluate cerebrospinal fluid (CSF) parameters, the need for less invasive diagnostic markers is well evident. To this respect, blood circulating cytokines or growth factors have provided some encouraging results, even though no clinically validated to date. In 2007 Ray et al suggested a panel of 18 circulating molecules that might increase AD diagnostic accuracy. In an attempt of replicating their data, we designed a multiplex fluorimetric assay comprising 16 independent analytes and covering 15 out of the 18 described proteins. We collected serum samples from three diagnostic groups: probable AD (n=33), matched healthy controls (CNT, n=23) and non AD demented (NAD, n=14). After correction for age, we found an increased level of EGF-1 in AD in comparison to CNT and NAD, while an increase of TRAIL-R4 was found in NAD. However, evaluation of specificity/ sensitivity by ROC curve analysis gave weak evidence of diagnostic accuracy (area under the curve = 0.63 and 0.66 for EGF and TRAIL-R4, respectively). Finally, we tried to find a diagnostic classifier by a multivariate algorithm. We found indication of diagnostic evidence for AD only, while NAD samples did not show a diagnostic pattern.",
keywords = "Alzheimer's disease, Artificial neural networks, Diagnosis, EGF-1, Machine learning, Multiplex analysis, Multivariate classifier, Peripheral biomarkers",
author = "Gloria Biella and Massimo Franceschi and {De Rino}, Francesca and Annalisa Davin and Giacomo Giacalone and Paola Brambilla and Panagiotis Bountris and Maria Haritou and Giuseppe Magnani and {Martinelli Boneschi}, Filippo and Gianluigi Forloni and Diego Albani",
year = "2013",
language = "English",
volume = "2",
pages = "40--45",
journal = "American Journal of Neurodegenerative Diseases",
issn = "2165-591X",
publisher = "e-Century Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease

AU - Biella, Gloria

AU - Franceschi, Massimo

AU - De Rino, Francesca

AU - Davin, Annalisa

AU - Giacalone, Giacomo

AU - Brambilla, Paola

AU - Bountris, Panagiotis

AU - Haritou, Maria

AU - Magnani, Giuseppe

AU - Martinelli Boneschi, Filippo

AU - Forloni, Gianluigi

AU - Albani, Diego

PY - 2013

Y1 - 2013

N2 - One of the current challenge in Alzheimer's disease (AD) is the identification of reliable biomarkers that might improve diagnostic accuracy, possibly correlating with the disease progression and patient's response to therapy. As the clinically validated AD biomarkers evaluate cerebrospinal fluid (CSF) parameters, the need for less invasive diagnostic markers is well evident. To this respect, blood circulating cytokines or growth factors have provided some encouraging results, even though no clinically validated to date. In 2007 Ray et al suggested a panel of 18 circulating molecules that might increase AD diagnostic accuracy. In an attempt of replicating their data, we designed a multiplex fluorimetric assay comprising 16 independent analytes and covering 15 out of the 18 described proteins. We collected serum samples from three diagnostic groups: probable AD (n=33), matched healthy controls (CNT, n=23) and non AD demented (NAD, n=14). After correction for age, we found an increased level of EGF-1 in AD in comparison to CNT and NAD, while an increase of TRAIL-R4 was found in NAD. However, evaluation of specificity/ sensitivity by ROC curve analysis gave weak evidence of diagnostic accuracy (area under the curve = 0.63 and 0.66 for EGF and TRAIL-R4, respectively). Finally, we tried to find a diagnostic classifier by a multivariate algorithm. We found indication of diagnostic evidence for AD only, while NAD samples did not show a diagnostic pattern.

AB - One of the current challenge in Alzheimer's disease (AD) is the identification of reliable biomarkers that might improve diagnostic accuracy, possibly correlating with the disease progression and patient's response to therapy. As the clinically validated AD biomarkers evaluate cerebrospinal fluid (CSF) parameters, the need for less invasive diagnostic markers is well evident. To this respect, blood circulating cytokines or growth factors have provided some encouraging results, even though no clinically validated to date. In 2007 Ray et al suggested a panel of 18 circulating molecules that might increase AD diagnostic accuracy. In an attempt of replicating their data, we designed a multiplex fluorimetric assay comprising 16 independent analytes and covering 15 out of the 18 described proteins. We collected serum samples from three diagnostic groups: probable AD (n=33), matched healthy controls (CNT, n=23) and non AD demented (NAD, n=14). After correction for age, we found an increased level of EGF-1 in AD in comparison to CNT and NAD, while an increase of TRAIL-R4 was found in NAD. However, evaluation of specificity/ sensitivity by ROC curve analysis gave weak evidence of diagnostic accuracy (area under the curve = 0.63 and 0.66 for EGF and TRAIL-R4, respectively). Finally, we tried to find a diagnostic classifier by a multivariate algorithm. We found indication of diagnostic evidence for AD only, while NAD samples did not show a diagnostic pattern.

KW - Alzheimer's disease

KW - Artificial neural networks

KW - Diagnosis

KW - EGF-1

KW - Machine learning

KW - Multiplex analysis

KW - Multivariate classifier

KW - Peripheral biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84980052289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980052289&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84980052289

VL - 2

SP - 40

EP - 45

JO - American Journal of Neurodegenerative Diseases

JF - American Journal of Neurodegenerative Diseases

SN - 2165-591X

IS - 1

ER -